Last updated: September 12, 2026
GIAPREZA, the commercial brand for synthetic human angiotensin II, is a specialized hospital product used to raise blood pressure in adults with distributive shock. Its market is driven by intensive-care-unit adoption, septic-shock treatment protocols, hospital formulary decisions, and the limited number of pharmacologic alternatives for patients who remain hypotensive despite conventional vasopressors.
Innoviva acquired GIAPREZA through its acquisition of La Jolla Pharmaceutical in 2022. Public filings indicate that GIAPREZA sales have grown from a small launch base into a product generating roughly $50 million to $70 million in annual net sales. The product has orphan-drug exclusivity, but that regulatory protection expired in 2024. Commercial access remains constrained by the narrow indication, hospital budget controls, clinical preference for lower-cost vasopressors, and the absence of broad outpatient use.
What is GIAPREZA and how is it used?
GIAPREZA is an intravenous formulation of angiotensin II. The FDA approved it in December 2017 for increasing blood pressure in adults with distributive shock. The drug is administered by continuous intravenous infusion and is titrated according to blood-pressure response.
| Attribute |
GIAPREZA |
| Active ingredient |
Angiotensin II |
| Brand owner |
Innoviva, Inc. |
| Original developer |
La Jolla Pharmaceutical Company |
| FDA approval |
December 2017 |
| Primary indication |
Increase blood pressure in adults with distributive shock |
| Administration |
Continuous intravenous infusion |
| Primary setting |
Intensive care units and acute-care hospitals |
| Key evidence |
ATHOS-3 Phase 3 trial |
| Main competitors |
Norepinephrine, vasopressin, epinephrine, phenylephrine, methylene blue |
| Regulatory exclusivity |
Orphan-drug exclusivity through 2024 |
| Commercial model |
Hospital and institutional sales |
The approval was based principally on ATHOS-3, a randomized study in patients with vasodilatory shock who had received substantial doses of conventional vasopressors. Angiotensin II produced a higher rate of blood-pressure response than placebo at the prespecified assessment point, although the trial was not designed to establish a mortality benefit.[1]
How large is the GIAPREZA market?
GIAPREZA operates in a narrow but clinically important segment of the hospital vasopressor market. The total market for vasopressors is much larger than the market for GIAPREZA because norepinephrine and vasopressin are used routinely and at materially lower cost.
GIAPREZA's addressable population consists mainly of patients with severe distributive shock who have inadequate blood-pressure control after conventional treatment. This creates a second-line or rescue-market profile rather than a broad first-line market.
Market demand is influenced by five factors:
- The annual number of patients with septic or other forms of vasodilatory shock.
- The share of hospitals that adopt angiotensin II in treatment protocols.
- Physician willingness to use a branded product after failure of lower-cost alternatives.
- Hospital pharmacy-and-therapeutics committee restrictions.
- Reimbursement and acquisition-cost economics.
The product's clinical value is highest in patients requiring multiple vasopressors. Its economic value is less compelling in patients who respond adequately to norepinephrine or vasopressin.
What has been GIAPREZA's financial trajectory?
Public company filings indicate a sustained increase in GIAPREZA net product sales following Innoviva's acquisition of La Jolla. The product benefits from an established hospital sales infrastructure and a growing body of real-world experience.
| Period |
Reported or publicly disclosed GIAPREZA sales trend |
Commercial interpretation |
| 2018-2019 |
Early commercial ramp |
Limited formulary penetration and launch-stage adoption |
| 2020-2021 |
Growth during expanded awareness of refractory shock treatment |
Increased ICU familiarity and broader hospital evaluation |
| 2022 |
Approximately $49 million |
First full commercial period under Innoviva ownership |
| 2023 |
Approximately $58 million to $60 million |
Continued account penetration and utilization growth |
| 2024 |
Approximately $65 million to $70 million range |
Growth offset by pricing, formulary controls, and the loss of orphan exclusivity |
Innoviva's filings report GIAPREZA sales within its portfolio of commercial products, which also includes XERAVA. The company has not treated GIAPREZA as a mass-market product. Revenue growth has depended on increasing utilization within existing hospital accounts, securing new formulary placements, and expanding physician familiarity.
The financial profile is attractive relative to a conventional generic injectable because the product is used in high-acuity situations where treatment decisions prioritize hemodynamic response and clinical urgency. The market is still limited by low treatment frequency relative to common hospital drugs.
What drives GIAPREZA revenue growth?
Hospital formulary expansion
GIAPREZA sales rise when hospitals move the product from restricted or exceptional-use status to a defined protocol for refractory distributive shock. Formulary placement does not guarantee high volume. Many hospitals maintain use criteria requiring failure of norepinephrine and vasopressin before angiotensin II is approved.
Clinical protocol adoption
The product is more likely to be used when critical-care physicians have standardized protocols for patients receiving multiple vasopressors. Protocol-driven use reduces physician-by-physician variability and improves product predictability.
Increasing recognition of refractory shock
Patients with vasodilatory shock may remain hypotensive despite high-dose catecholamines and vasopressin. GIAPREZA's mechanism gives clinicians another option in this setting. Increased awareness of refractory shock can expand the product's use without changing the FDA label.
Hospital contracting
Purchasing agreements, distributor terms, and hospital-system contracts affect realized net sales. Large integrated delivery networks can exert pricing pressure, particularly when the product is not protected by a broad exclusivity barrier.
What competitive products challenge GIAPREZA?
GIAPREZA competes with established vasopressors and off-label rescue therapies rather than with a single direct branded rival.
| Treatment |
Position in shock care |
Competitive effect on GIAPREZA |
| Norepinephrine |
Common first-line vasopressor |
Major price and standard-of-care barrier |
| Vasopressin |
Common adjunctive vasopressor |
Reduces demand for second-line therapies |
| Epinephrine |
Alternative or adjunctive vasopressor |
Used in selected shock settings |
| Phenylephrine |
Vasoconstrictor used in selected patients |
Competes in certain hemodynamic profiles |
| Methylene blue |
Off-label rescue treatment |
Competes in refractory vasoplegia |
| Corticosteroids |
Adjunctive treatment in selected shock cases |
May reduce escalation to additional agents |
| Angiotensin II |
Approved option for distributive shock |
Differentiated but generally reserved for severe cases |
Norepinephrine remains the central benchmark. Its low cost, broad physician familiarity, and inclusion in treatment guidelines make it difficult for GIAPREZA to move into first-line use.
GIAPREZA's strongest commercial position is as an adjunct or rescue therapy after inadequate response to conventional vasopressors. Its weakest position is in uncomplicated distributive shock that responds to initial treatment.
What is the FDA regulatory status of GIAPREZA?
The FDA approved GIAPREZA under the traditional approval pathway in 2017. The indication is limited to increasing blood pressure in adults with distributive shock.
The product did not receive approval for mortality reduction, reversal of shock, or treatment of all forms of hypotension. This distinction matters commercially because hospital protocols may evaluate the product on blood-pressure response, vasopressor reduction, organ support, ICU length of stay, and survival outcomes.
GIAPREZA received orphan-drug designation for its approved use. Orphan-drug exclusivity generally lasts seven years from approval. For a product approved in December 2017, that exclusivity period ran through December 2024, subject to the specific FDA exclusivity record.[2]
The loss of orphan exclusivity removes a regulatory barrier to approval of another sponsor's product for the same orphan indication. It does not itself create a generic product or eliminate patents, formulation rights, manufacturing know-how, or commercial barriers.
What patents protect GIAPREZA?
GIAPREZA's protection depends on a combination of patent rights, regulatory exclusivity, formulation and manufacturing know-how, and the practical difficulty of developing and validating an injectable peptide product.
The relevant protection categories are:
- Patents covering angiotensin II compositions or formulations.
- Patents covering treatment of hypotension or distributive shock.
- Patents covering dosing, titration, or administration.
- Manufacturing and quality-control processes for synthetic peptide drug substance.
- Trade-secret information involving sterile formulation, stability, scale-up, and release testing.
Patent risk analysis must distinguish between a patent that covers the active ingredient broadly and a patent that covers only a specific formulation or method of use. A method-of-use patent may be difficult to enforce against a hospital or physician because treatment-use evidence may not be visible in the product itself. A formulation patent can present a more direct barrier if the competing product uses the same protected composition.
Public Orange Book data should be reviewed for the current list of patents, expiration dates, pediatric extensions, and any certifications associated with an abbreviated new drug application. The expiration of orphan exclusivity does not establish that GIAPREZA is free of patent protection.
Has GIAPREZA faced Paragraph IV challenges?
A Paragraph IV challenge would require an ANDA applicant to certify that a listed patent is invalid, unenforceable, or will not be infringed. Publicly available company disclosures have not established a major, commercially consequential Paragraph IV litigation campaign against GIAPREZA comparable to the patent disputes surrounding high-revenue small-molecule products.
The risk is still relevant because the product has a limited but growing revenue base and the approved drug is an injectable. A challenger would need to address:
- Bioequivalence for the injectable product.
- Peptide identity and potency.
- Sterility and endotoxin specifications.
- Impurity profile.
- Container-closure compatibility.
- Stability through the proposed shelf life.
- Manufacturing consistency at commercial scale.
An ANDA applicant may also pursue a section viii statement for an unprotected indication or avoid a method-of-use patent through labeling. That strategy would be less straightforward for GIAPREZA because the approved use is concentrated in the product's core hospital application.
What generic entry risks exist for GIAPREZA?
Generic entry risk is moderate rather than immediate and binary.
Near-term risk
The product's orphan exclusivity has expired, creating a pathway for competing approvals. However, the commercial market is relatively small, and injectable peptide development requires specialized manufacturing, regulatory, and quality infrastructure.
Medium-term risk
The most credible entrants are established injectable manufacturers with sterile manufacturing capacity, hospital distribution, and experience with complex generics. Potential competitors could include large generic companies, specialty injectable manufacturers, and contract-development partners operating under their own abbreviated applications.
Commercial launch scenarios
| Scenario |
Timing profile |
Market effect |
| No approved competitor |
Continued branded growth |
Innoviva retains most hospital demand |
| One approved competitor without rapid uptake |
Limited erosion |
Hospitals gain negotiation leverage |
| Multiple injectable competitors |
Material price pressure |
Net sales and gross margin decline |
| Patent settlement with delayed entry |
Protected revenue period |
Entry date becomes the key valuation variable |
| Successful 180-day first-filer launch |
Sharp initial erosion |
Discounting and formulary substitution increase |
A generic entrant would not need to replace all GIAPREZA use to affect pricing. Large hospital systems could use even the availability of an alternative to renegotiate contracts.
What licensing deals and ownership changes affect GIAPREZA?
La Jolla was the original commercial owner of GIAPREZA. Innoviva acquired La Jolla in 2022 in a transaction valued at approximately $149 million, including assumed debt and other transaction considerations reported by the parties.[3]
The transaction transferred control of GIAPREZA and La Jolla's commercial portfolio to Innoviva. It also changed the product's strategic position from a standalone biotechnology asset to a component of Innoviva's hospital-focused commercial portfolio.
Regional commercialization arrangements may affect sales outside the United States. The value of those arrangements depends on local reimbursement, hospital procurement systems, regulatory status, and the ability of a partner to support critical-care adoption.
How strong is the GIAPREZA patent and commercial estate?
The commercial estate is stronger than the orphan-drug designation alone but weaker than the estate of a high-revenue product with broad composition-of-matter protection extending well beyond the approval date.
Strengths
- FDA-approved indication in a severe hospital condition.
- Differentiated mechanism among vasopressors.
- Specialized sterile injectable manufacturing.
- Established hospital accounts and physician familiarity.
- Clinical utility in patients inadequately controlled with conventional agents.
- Operational barriers for smaller generic companies.
Weaknesses
- Limited indication and low treatment frequency.
- Dependence on hospital formulary approval.
- Competition from inexpensive standard therapies.
- Expired orphan exclusivity.
- Potential for off-label substitutes.
- Modest annual revenue compared with products that attract numerous generic applicants.
The main protection is therefore layered. Patent rights may delay or complicate entry, but clinical positioning, manufacturing complexity, and hospital contracting are equally important to the product's economic durability.
What is the likely GIAPREZA generic launch outlook?
The most likely launch pattern is gradual rather than an immediate market collapse. A first entrant could initially target hospitals with high GIAPREZA utilization and negotiate discounts through group purchasing organizations. Innoviva could preserve a portion of demand through contracts, clinical support, supply reliability, and physician preference.
If several competitors launch, the product could face a rapid decline in price and a slower decline in volume. Hospitals may retain GIAPREZA for high-risk patients while substituting a lower-priced product for protocol-driven cases.
A delayed-entry settlement, if reached, would be commercially important. The relevant variables would include the entry date, authorized-generic rights, supply terms, and restrictions on the competing product's label.
How does GIAPREZA compare with XERAVA?
GIAPREZA and XERAVA are both Innoviva products acquired through La Jolla, but their markets differ.
| Factor |
GIAPREZA |
XERAVA |
| Therapeutic area |
Critical-care hemodynamics |
Complicated intra-abdominal infection |
| Active ingredient |
Angiotensin II |
Eravacycline |
| Primary setting |
ICU and hospital critical care |
Inpatient infectious disease |
| Main competition |
Generic vasopressors and off-label therapies |
Established antibiotics and generic agents |
| Use pattern |
Rescue or adjunctive therapy |
Defined antibacterial treatment course |
| Key commercial driver |
Protocol adoption and refractory shock use |
Antimicrobial positioning and stewardship |
| Generic risk |
Injectable peptide and formulation complexity |
Antibiotic competition and patent timing |
GIAPREZA is more dependent on critical-care protocol adoption. XERAVA has a broader anti-infective commercial framework but faces intense competition from established antibiotics.
What is the revenue exposure for Innoviva?
GIAPREZA is strategically important but not the sole driver of Innoviva's financial performance. Innoviva's broader revenue base includes royalties and commercial product sales. That structure reduces the company's dependence on a single hospital product, while GIAPREZA remains material within the La Jolla portfolio.
The principal downside risks are:
- A competing injectable angiotensin II product.
- Hospital price concessions.
- Reduced use after failure of conventional vasopressors.
- Negative evidence on survival or resource utilization.
- Manufacturing interruptions.
- A decline in ICU admissions or changes in shock-treatment protocols.
The principal upside drivers are:
- Increased protocol adoption.
- More use in high-dose vasopressor patients.
- New evidence supporting earlier treatment.
- Improved recognition of angiotensin II's role in vasodilatory shock.
- Expansion of international hospital access.
Key Takeaways
- GIAPREZA is an FDA-approved intravenous angiotensin II product for adults with distributive shock.
- Its market is specialized, hospital-based, and concentrated in refractory or vasopressor-dependent patients.
- Innoviva acquired the product through its 2022 purchase of La Jolla Pharmaceutical.
- Public filings indicate annual GIAPREZA sales increased from roughly $49 million in 2022 to approximately $58 million to $60 million in 2023, with 2024 sales in the mid-$60 million range.
- Orphan-drug exclusivity expired in 2024, increasing long-term generic risk.
- Generic entry remains constrained by injectable peptide development, sterile manufacturing, clinical protocol requirements, and a relatively modest revenue pool.
- Norepinephrine and vasopressin are the principal commercial barriers because they are established, inexpensive, and widely used.
- GIAPREZA's durability depends on layered protection: patents, manufacturing capability, formulary access, hospital contracts, and clinical adoption.
- A single competing injectable could pressure pricing before it materially displaces volume.
- Multiple entrants would create the greatest risk to net sales and gross margin.
FAQs
Is GIAPREZA a biologic or a small-molecule drug?
GIAPREZA is a synthetic peptide drug. It is not generally treated as a conventional monoclonal-antibody biologic, but its peptide identity and sterile injectable presentation create manufacturing and regulatory complexity.
Can hospitals substitute norepinephrine for GIAPREZA?
Norepinephrine is commonly used before GIAPREZA and remains the standard first-line vasopressor for many patients with distributive shock. GIAPREZA is generally considered when conventional vasopressors do not provide adequate blood-pressure control.
Does the expiration of orphan exclusivity make GIAPREZA generic?
No. Orphan exclusivity expiration removes one FDA regulatory barrier, but a competitor must still obtain approval and address any unexpired patents, formulation requirements, manufacturing controls, and bioequivalence issues.
What would most quickly reduce GIAPREZA revenue?
The fastest revenue pressure would likely come from an approved competing injectable angiotensin II product adopted by large hospital systems. Broad formulary restrictions or evidence that limits use to a narrower patient population could also reduce sales.
Is GIAPREZA exposed to biosimilar competition?
GIAPREZA is not exposed to biosimilar competition in the same manner as a monoclonal antibody or other licensed biologic. Any direct competitor would more likely pursue an abbreviated or comparable approval pathway applicable to the product's regulatory classification and dosage form.
References
-
Khanna, A., English, S. W., Wang, X. S., Ham, K., Tumlin, J., Szerlip, H., Busse, L. W., Slotki, I., Wang, H., Tuttle, K. R., Ince, C., & Fülöp, T. (2017). Angiotensin II for the treatment of vasodilatory shock. The New England Journal of Medicine, 377(5), 419-430. https://doi.org/10.1056/NEJMoa1704154
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Giapreza (angiotensin II). https://www.accessdata.fda.gov/scripts/cder/daf/
-
Innoviva, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
Innoviva, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
